The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
Journal Article
·
· Journal of Medicinal Chemistry
- Amgen Inc., 360 Binney Street, Cambridge Massachusetts 02142, United States
- Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- INDUSTRY
- OSTI ID:
- 1495460
- Journal Information:
- Journal of Medicinal Chemistry, Vol. 55, Issue 14; ISSN 0022-2623
- Publisher:
- American Chemical Society (ACS)
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
Discovery of Potent, Selective, and Brain-Penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
Journal Article
·
Wed Sep 18 00:00:00 EDT 2013
· J. Med. Chem.
·
OSTI ID:1495460
+17 more
Discovery of Potent, Selective, and Brain-Penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors
Journal Article
·
Wed Jan 01 00:00:00 EST 2020
· Journal of Medicinal Chemistry
·
OSTI ID:1495460
+6 more
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
Journal Article
·
Wed Aug 03 00:00:00 EDT 2011
· Journal of Medicinal Chemistry
·
OSTI ID:1495460
+22 more